HIKAL
|
|
BOM : 524735     NSE : HIKAL     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Nov 19,2024 |
Price(EOD): ₹ 392.20
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 4,835.83 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
HIKAL | 1.9% | 3.4% | 43.6% |
SUN PHARMACEUTICAL INDUSTRIES | -1.4% | -7.1% | 48% |
CIPLA | -3.5% | -5.2% | 18% |
DR REDDYS LABORATORIES | -3.9% | -10.1% | 10.1% |
ZYDUS LIFESCIENCES | -0.3% | -7.3% | 52.2% |
DIVIS LABORATORIES | 1.5% | -2.1% | 63% |
MANKIND PHARMA | -2.3% | -3% | 39.6% |
TORRENT PHARMACEUTICALS | -1.8% | -10.2% | 51.3% |
LUPIN | -2.4% | -6.4% | 73.9% |
FUNDAMENTAL ANALYSIS OF HIKAL
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF HIKAL
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
65.79
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 73.51 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] 4.07
P/B Calculated based on Book Value of Rs 1,187.66 Cr
[Latest Year - Mar2024 - Consolidated Results ] 2.66
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,821.37 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
207% 101% 115% |
SHARE PRICE MOMENTUM OF HIKAL
HIKAL vs SENSEX
DEBT OF HIKAL
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.69 0.66 0.63 0.66 |
0.69 0.66 0.63 0.66 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF HIKAL
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF HIKAL
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
11.33% 29.14% 259.42% 258.82% |
4.14% 30.03% 46.75% 45.24% |
QtrlyTrend |
8 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
HIKAL related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
S&P BSE HEALTHCARE | -2.5% | -4% | 46.8% |
S&P BSE MIDSMALLCAP | -2.9% | -7% | 35.6% |
S&P BSE SMALL CAP | -3.3% | -7.2% | 35.2% |
You may also like the below Video Courses
FAQ about HIKAL
Is HIKAL good for long term investment?
As on Nov 19,2024, the Fundamentals of HIKAL look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of HIKAL . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is HIKAL UnderValued or OverValued?
As on Nov 19,2024, HIKAL is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of HIKAL ?
As on Nov 19,2024, the Intrinsic Value of HIKAL is Rs. 182.72 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 127.83
Fair Value [Median EV / Sales Model] : Rs. 195.49
Fair Value [Median Price / Sales Model] : Rs. 182.72
Estimated Median Fair Value of HIKAL : Rs. 182.72
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.